businesswire.comAlto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial4 months ago
businesswire.comAlto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial4 months ago
businesswire.comAlto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology6 months ago
businesswire.comAlto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology6 months ago
businesswire.comAlto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights7 months ago
prnewswire.comANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm7 months ago
businesswire.comANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm7 months ago
businesswire.comANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm7 months ago
businesswire.comAlto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder7 months ago